<?xml version='1.0' encoding='utf-8'?>
<document id="10092958"><sentence text="Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug."><entity charOffset="29-38" id="DDI-PubMed.10092958.s1.e0" text="meloxicam" /></sentence><sentence text="Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine -3-carboxamide-1, 1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2" /><sentence text=" Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration"><entity charOffset="1-10" id="DDI-PubMed.10092958.s3.e0" text="Meloxicam" /></sentence><sentence text=" Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces"><entity charOffset="1-10" id="DDI-PubMed.10092958.s4.e0" text="Meloxicam" /></sentence><sentence text=" Meloxicam and its metabolites bind extensively to plasma albumin"><entity charOffset="1-10" id="DDI-PubMed.10092958.s5.e0" text="Meloxicam" /></sentence><sentence text=" Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies"><entity charOffset="31-40" id="DDI-PubMed.10092958.s6.e0" text="meloxicam" /></sentence><sentence text=" Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam"><entity charOffset="94-103" id="DDI-PubMed.10092958.s7.e0" text="meloxicam" /></sentence><sentence text=" Dosage adjustment is not required in the elderly" /><sentence text=" Drug-drug interaction studies are available for some commonly co-prescribed medications" /><sentence text=" Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID" /><sentence text="" /></document>